var data={"title":"Quadrivalent meningococcal polysaccharide vaccine (unconjugated/carrier-free) (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Quadrivalent meningococcal polysaccharide vaccine (unconjugated/carrier-free) (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6525?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=quadrivalent-meningococcal-polysaccharide-vaccine-unconjugated-carrier-free-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Quadrivalent meningococcal polysaccharide vaccine (unconjugated/carrier-free) (United States: Not available): Patient drug information&quot;</a> and <a href=\"topic.htm?path=quadrivalent-meningococcal-polysaccharide-vaccine-unconjugated-carrier-free-united-states-not-available-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Quadrivalent meningococcal polysaccharide vaccine (unconjugated/carrier-free) (United States: Not available): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192529\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Menomune-A/C/Y/W-135 [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12592967\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Menomune-A/C/Y/W-135 [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192543\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vaccine;</li>\n      <li>\n        Vaccine, Inactivated (Bacterial)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192532\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Immunization:</b> SubQ: 0.5 mL/dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>ACIP recommendations (CDC/ACIP [Cohn 2013]):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults &lt;56 years: Not routinely recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults &ge;56 years: Meningococcal polysaccharide vaccine (MPSV4, Menomune) is preferred for meningococcal vaccine-naive persons in this age group who are at increased risk of meningococcal infection and require a single dose (eg, travelers or during a community outbreak). Persons previously vaccinated with a quadrivalent meningococcal conjugate vaccine (MenACWY, Menveo, or Menactra) and who require revaccination or for whom multiple doses are anticipated, MenACWY-D (Menactra) is preferred (eg, persons with asplenia or microbiologists).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192539\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=quadrivalent-meningococcal-polysaccharide-vaccine-unconjugated-carrier-free-united-states-not-available-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Quadrivalent meningococcal polysaccharide vaccine (unconjugated/carrier-free) (United States: Not available): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">\n      <b>Immunization:</b> Children &ge;2 years and Adolescents: SubQ: 0.5 mL/dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">\n      <b>ACIP recommendations (CDC/ACIP [Cohn 2013]):</b> Children and Adolescents: Not routinely recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192533\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16317920\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16317921\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192514\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, powder for reconstitution [MPSV4]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Menomune-A/C/Y/W-135: 50 mcg each of polysaccharide antigen groups A, C, Y, and W-135 per 0.5 mL dose [contains lactose 2.5-5 mg/0.5 mL, natural rubber/natural latex in packaging, thimerosal in diluent for multidose vial] [DSC]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192501\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192517\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Administer by SubQ injection to the deltoid region; do not administer intradermally, IM, or IV. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192515\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningococcal disease prevention:</b> Active immunization of patients 2 years and older to prevent invasive meningococcal disease caused by <i>Neisseria meningitidis</i> serogroups A, C, Y, and W-135. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for persons at increased risk for meningococcal disease. Meningococcal quadrivalent conjugate vaccine (MenACWY; Menactra, Menveo) is preferred; meningococcal polysaccharide vaccine (MPSV4; Menomune) is preferred in meningococcal vaccine-naive adults &ge;56 years of age requiring only a single vaccination (CDC/ACIP [Cohn 2013]).  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">Those at increased risk of meningococcal disease include the following:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">- Persons &ge;2 months of age with medical conditions such as anatomical or functional asplenia or persistent compliment component deficiencies (eg, C<sub>5</sub>-C<sub>9</sub>, properdin, factor H, or factor D)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">- Persons &ge;9 months of age that travel to or reside in countries where meningococcal disease is hyperendemic or epidemic, especially if contact with the local population will be prolonged</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">- Unvaccinated or incompletely vaccinated first year college students living in residence halls</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">- Military recruits</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">- Microbiologists with occupational exposure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">- Persons (in all recommended age groups) at risk who are part of outbreaks caused by vaccine preventable serogroups</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3343700\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">MPSV (meningococcal polysaccharide vaccine; MPSV4 is the correct abbreviation) may be confused with MCV4 (meningococcal ACWY conjugate vaccine)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">MPSV (meningococcal polysaccharide vaccine; MPSV4 is the correct abbreviation) may be confused with MMRV (measles, mumps, rubella, and varicella vaccine)</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issue:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Menomune (MPSV4) should be administered by subcutaneous (SubQ) injection. Menactra and Menveo (MCV4), a conjugate vaccine, is to be administered by intramuscular (IM) injection only.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192508\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (29% to 42%), fatigue (children &ge;11 years, adolescents, and adults: 25% to 32%), malaise (children &ge;11 years, adolescents, and adults: 17% to 22%), irritability (children 2 to 10 years: 12%), drowsiness (children 2 to 10 years: 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (10% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (adults: 48%; children and adolescents 2 to 18 years: 26% to 29%), erythema at injection site (adults: 16%; children and adolescents 2 to 18 years: 6% to 8%), induration at injection site (4% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (adults: 16%; children and adolescents 2 to 18 years: 5% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Chills (children &ge;11 years, adolescents, and adults: 4% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (children and adolescents 2 to 18 years: 1% to 3%; adults: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia (8% to 10%), vomiting (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Swelling at injection site (3% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (children and adolescents 2 to 18 years: 3% to 5%; adults: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing and/or case reports: Dizziness, Guillain-Barr&eacute; syndrome, hypersensitivity (angioedema, dyspnea, pruritus, rash, urticaria), myalgia, nausea, paresthesia, vasodepressor syncope, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192520\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192505\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Meningococcal infections: Not to be used to treat meningococcal infections or to provide immunity against <i>N. meningitidis</i> serogroup B.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Consider deferring immunization during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines (IDSA [Rubin 2014]). Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: Packaging may contain natural latex rubber.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thimerosal: Some dosage forms contain thimerosal.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the ACIP Recommended Immunization Schedules (ACIP [Kim 2017]; CDC/ACIP [Robinson 2017]). Specific recommendations for use of this vaccine in immunocompromised patients with asplenia, cerebrospinal fluid leaks, cochlear implants, or sickle cell disease are available from the IDSA (Rubin 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299663\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192509\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9606&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192511\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192523\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Inactivated bacterial vaccines have not been shown to cause increased risks to the fetus (ACIP [Kroger 2017]). Pregnancy should not preclude vaccination if indicated (CDC/ACIP [Cohn 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12602100\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if this vaccine is present in breast milk. The manufacturer recommends that caution be used if administered to a breastfeeding woman. Administration does not affect the safety of breastfeeding for the mother or the infant. Breastfeeding infants should be vaccinated according to the recommended schedules (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6871803\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192504\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Induces the formation of bactericidal antibodies to meningococcal antigens; the presence of these antibodies is strongly correlated with immunity to meningococcal disease caused by <i>Neisseria meningitidis</i> groups A, C, Y and W-135.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F192519\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Antibody levels: 7-10 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Antibodies against group A and C polysaccharides decline markedly (to prevaccination levels) over the first 3 years following a single dose of vaccine, especially in children &lt;4 years of age</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46220882\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Mencevax (FR, IN, PK, ZA);</li>\n      <li>Mencevax ACWY (AE, AT, AU, CH, DE, FI, HK, HU, ID, IL, IT, KW, LB, LK, MY, NZ, PH, QA, RU, SA, SG, SI);</li>\n      <li>Menomune (AU, BB, IL, MY, PH, TH, ZA);</li>\n      <li>Menomune ACYW-135 (NZ);</li>\n      <li>Menwayc (CN);</li>\n      <li>Yu Nao Ning (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Cohn AC, MacNeil JR, Clark TA, et al; Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2013;62(RR-2):1-28. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quadrivalent-meningococcal-polysaccharide-vaccine-unconjugated-carrier-free-united-states-not-available-drug-information/abstract-text/23515099/pubmed\" target=\"_blank\" id=\"23515099\">23515099</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim DK, Riley LE, Harriman KH, et al; Advisory Committee on Immunization Practices (ACIP), ACIP Adult Immunization Work Group. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older&mdash;United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017; 66(5):136-138. doi: 10.15585/mmwr.mm6605e2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quadrivalent-meningococcal-polysaccharide-vaccine-unconjugated-carrier-free-united-states-not-available-drug-information/abstract-text/28182599/pubmed\" target=\"_blank\" id=\"28182599\">28182599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Menomune (meningococcal polysaccharide A/C/YW-135) [prescribing information]. Swiftwater, PA: Sanofi Pasteur; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo; <i>Lancet</i>, 2009, 374(9698):1339-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quadrivalent-meningococcal-polysaccharide-vaccine-unconjugated-carrier-free-united-states-not-available-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson CL, Romero JR, Kempe A, et al; Advisory Committee on Immunization Practices (ACIP), ACIP Child/Adolescent Immunization Work Group. Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):134-135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quadrivalent-meningococcal-polysaccharide-vaccine-unconjugated-carrier-free-united-states-not-available-drug-information/abstract-text/28182607/pubmed\" target=\"_blank\" id=\"28182607\">28182607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/quadrivalent-meningococcal-polysaccharide-vaccine-unconjugated-carrier-free-united-states-not-available-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9606 Version 90.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F192529\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F12592967\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F192543\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F192532\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F192539\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F192533\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16317920\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16317921\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F192514\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F192501\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F192517\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F192515\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3343700\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F192508\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F192520\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F192505\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299663\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F192509\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F192511\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F192523\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F12602100\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F6871803\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F192504\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F192519\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F46220882\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9606|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=quadrivalent-meningococcal-polysaccharide-vaccine-unconjugated-carrier-free-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Quadrivalent meningococcal polysaccharide vaccine (unconjugated/carrier-free) (United States: Not available): Patient drug information</a></li><li><a href=\"topic.htm?path=quadrivalent-meningococcal-polysaccharide-vaccine-unconjugated-carrier-free-united-states-not-available-pediatric-drug-information\" class=\"drug drug_pediatric\">Quadrivalent meningococcal polysaccharide vaccine (unconjugated/carrier-free) (United States: Not available): Pediatric drug information</a></li></ul></div></div>","javascript":null}